Hodrea and colleagues [154] demonstrated that the treatment with SGLT2 inhibitor dapaglifozin significantly ameliorates DKD progression in a model of streptozocin-induced diabetes. This evidence concerns the gene SLC5A2 and diabetic kidney disease.